Charting the road forward in psychiatric neurosurgery: Proceedings of the 2016 American Society for Stereotactic and Functional Neurosurgery workshop on neuromodulation for psychiatric disorders

Ausaf A. Bari, Charles B. Mikell, Aviva Abosch, Sharona Ben-Haim, Robert J. Buchanan, Allen W. Burton, Stephen Carcieri, G. Rees Cosgrove, Pierre Francois D'Haese, Zafiris Jeffrey Daskalakis, Emad N. Eskandar, Jason L. Gerrard, Wayne K. Goodman, Benjamin David Greenberg, Robert E. Gross, Clement Hamani, Zelma H.T. Kiss, Peter Konrad, Brian H. Kopell, Lothar KrinkeJean Philippe Langevin, Andres M. Lozano, Donald Malone, Helen S. Mayberg, Jonathan P. Miller, Parag G. Patil, Delea Peichel, Erika A. Petersen, Ali R. Rezai, R. Mark Richardson, Patricio Riva-Posse, Tejas Sankar, Jason M. Schwalb, Helen Blair Simpson, Konstantin Slavin, Paul H. Stypulkowski, Tor Tosteson, Peter Warnke, Jon T. Willie, Kareem A. Zaghloul, Joseph S. Neimat, Nader Pouratian, Sameer A. Sheth

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Objective Refractory psychiatric disease is a major cause of morbidity and mortality worldwide, and there is a great need for new treatments. In the last decade, investigators piloted novel deep brain stimulation (DBS)-based therapies for depression and obsessive-compulsive disorder (OCD). Results from recent pivotal trials of these therapies, however, did not demonstrate the degree of efficacy expected from previous smaller trials. To discuss next steps, neurosurgeons, neurologists, psychiatrists and representatives from industry convened a workshop sponsored by the American Society for Stereotactic and Functional Neurosurgery in Chicago, Illinois, in June of 2016. Design Here we summarise the proceedings of the workshop. Participants discussed a number of issues of importance to the community. First, we discussed how to interpret results from the recent pivotal trials of DBS for OCD and depression. We then reviewed what can be learnt from lesions and closed-loop neurostimulation. Subsequently, representatives from the National Institutes of Health, the Food and Drug Administration and industry discussed their views on neuromodulation for psychiatric disorders. In particular, these third parties discussed their criteria for moving forward with new trials. Finally, we discussed the best way of confirming safety and efficacy of these therapies, including registries and clinical trial design. We close by discussing next steps in the journey to new neuromodulatory therapies for these devastating illnesses. Conclusion Interest and motivation remain strong for deep brain stimulation for psychiatric disease. Progress will require coordinated efforts by all stakeholders.

Original languageEnglish (US)
Pages (from-to)886-896
Number of pages11
JournalJournal of Neurology, Neurosurgery and Psychiatry
Volume89
Issue number8
DOIs
StatePublished - Aug 1 2018

Fingerprint

Neurosurgery
Psychiatry
Deep Brain Stimulation
Education
Obsessive-Compulsive Disorder
Depression
Therapeutics
National Institutes of Health (U.S.)
Drug Industry
United States Food and Drug Administration
Registries
Motivation
Industry
Research Personnel
Clinical Trials
Morbidity
Safety
Mortality

Keywords

  • Depression
  • Electrical stimulation
  • Psychiatry
  • Stereotaxic surgery

ASJC Scopus subject areas

  • Surgery
  • Clinical Neurology
  • Psychiatry and Mental health

Cite this

Charting the road forward in psychiatric neurosurgery : Proceedings of the 2016 American Society for Stereotactic and Functional Neurosurgery workshop on neuromodulation for psychiatric disorders. / Bari, Ausaf A.; Mikell, Charles B.; Abosch, Aviva; Ben-Haim, Sharona; Buchanan, Robert J.; Burton, Allen W.; Carcieri, Stephen; Cosgrove, G. Rees; D'Haese, Pierre Francois; Daskalakis, Zafiris Jeffrey; Eskandar, Emad N.; Gerrard, Jason L.; Goodman, Wayne K.; Greenberg, Benjamin David; Gross, Robert E.; Hamani, Clement; Kiss, Zelma H.T.; Konrad, Peter; Kopell, Brian H.; Krinke, Lothar; Langevin, Jean Philippe; Lozano, Andres M.; Malone, Donald; Mayberg, Helen S.; Miller, Jonathan P.; Patil, Parag G.; Peichel, Delea; Petersen, Erika A.; Rezai, Ali R.; Richardson, R. Mark; Riva-Posse, Patricio; Sankar, Tejas; Schwalb, Jason M.; Simpson, Helen Blair; Slavin, Konstantin; Stypulkowski, Paul H.; Tosteson, Tor; Warnke, Peter; Willie, Jon T.; Zaghloul, Kareem A.; Neimat, Joseph S.; Pouratian, Nader; Sheth, Sameer A.

In: Journal of Neurology, Neurosurgery and Psychiatry, Vol. 89, No. 8, 01.08.2018, p. 886-896.

Research output: Contribution to journalArticle

Bari, AA, Mikell, CB, Abosch, A, Ben-Haim, S, Buchanan, RJ, Burton, AW, Carcieri, S, Cosgrove, GR, D'Haese, PF, Daskalakis, ZJ, Eskandar, EN, Gerrard, JL, Goodman, WK, Greenberg, BD, Gross, RE, Hamani, C, Kiss, ZHT, Konrad, P, Kopell, BH, Krinke, L, Langevin, JP, Lozano, AM, Malone, D, Mayberg, HS, Miller, JP, Patil, PG, Peichel, D, Petersen, EA, Rezai, AR, Richardson, RM, Riva-Posse, P, Sankar, T, Schwalb, JM, Simpson, HB, Slavin, K, Stypulkowski, PH, Tosteson, T, Warnke, P, Willie, JT, Zaghloul, KA, Neimat, JS, Pouratian, N & Sheth, SA 2018, 'Charting the road forward in psychiatric neurosurgery: Proceedings of the 2016 American Society for Stereotactic and Functional Neurosurgery workshop on neuromodulation for psychiatric disorders', Journal of Neurology, Neurosurgery and Psychiatry, vol. 89, no. 8, pp. 886-896. https://doi.org/10.1136/jnnp-2017-317082
Bari, Ausaf A. ; Mikell, Charles B. ; Abosch, Aviva ; Ben-Haim, Sharona ; Buchanan, Robert J. ; Burton, Allen W. ; Carcieri, Stephen ; Cosgrove, G. Rees ; D'Haese, Pierre Francois ; Daskalakis, Zafiris Jeffrey ; Eskandar, Emad N. ; Gerrard, Jason L. ; Goodman, Wayne K. ; Greenberg, Benjamin David ; Gross, Robert E. ; Hamani, Clement ; Kiss, Zelma H.T. ; Konrad, Peter ; Kopell, Brian H. ; Krinke, Lothar ; Langevin, Jean Philippe ; Lozano, Andres M. ; Malone, Donald ; Mayberg, Helen S. ; Miller, Jonathan P. ; Patil, Parag G. ; Peichel, Delea ; Petersen, Erika A. ; Rezai, Ali R. ; Richardson, R. Mark ; Riva-Posse, Patricio ; Sankar, Tejas ; Schwalb, Jason M. ; Simpson, Helen Blair ; Slavin, Konstantin ; Stypulkowski, Paul H. ; Tosteson, Tor ; Warnke, Peter ; Willie, Jon T. ; Zaghloul, Kareem A. ; Neimat, Joseph S. ; Pouratian, Nader ; Sheth, Sameer A. / Charting the road forward in psychiatric neurosurgery : Proceedings of the 2016 American Society for Stereotactic and Functional Neurosurgery workshop on neuromodulation for psychiatric disorders. In: Journal of Neurology, Neurosurgery and Psychiatry. 2018 ; Vol. 89, No. 8. pp. 886-896.
@article{d17d72a066064beaa23f15d33f08871f,
title = "Charting the road forward in psychiatric neurosurgery: Proceedings of the 2016 American Society for Stereotactic and Functional Neurosurgery workshop on neuromodulation for psychiatric disorders",
abstract = "Objective Refractory psychiatric disease is a major cause of morbidity and mortality worldwide, and there is a great need for new treatments. In the last decade, investigators piloted novel deep brain stimulation (DBS)-based therapies for depression and obsessive-compulsive disorder (OCD). Results from recent pivotal trials of these therapies, however, did not demonstrate the degree of efficacy expected from previous smaller trials. To discuss next steps, neurosurgeons, neurologists, psychiatrists and representatives from industry convened a workshop sponsored by the American Society for Stereotactic and Functional Neurosurgery in Chicago, Illinois, in June of 2016. Design Here we summarise the proceedings of the workshop. Participants discussed a number of issues of importance to the community. First, we discussed how to interpret results from the recent pivotal trials of DBS for OCD and depression. We then reviewed what can be learnt from lesions and closed-loop neurostimulation. Subsequently, representatives from the National Institutes of Health, the Food and Drug Administration and industry discussed their views on neuromodulation for psychiatric disorders. In particular, these third parties discussed their criteria for moving forward with new trials. Finally, we discussed the best way of confirming safety and efficacy of these therapies, including registries and clinical trial design. We close by discussing next steps in the journey to new neuromodulatory therapies for these devastating illnesses. Conclusion Interest and motivation remain strong for deep brain stimulation for psychiatric disease. Progress will require coordinated efforts by all stakeholders.",
keywords = "Depression, Electrical stimulation, Psychiatry, Stereotaxic surgery",
author = "Bari, {Ausaf A.} and Mikell, {Charles B.} and Aviva Abosch and Sharona Ben-Haim and Buchanan, {Robert J.} and Burton, {Allen W.} and Stephen Carcieri and Cosgrove, {G. Rees} and D'Haese, {Pierre Francois} and Daskalakis, {Zafiris Jeffrey} and Eskandar, {Emad N.} and Gerrard, {Jason L.} and Goodman, {Wayne K.} and Greenberg, {Benjamin David} and Gross, {Robert E.} and Clement Hamani and Kiss, {Zelma H.T.} and Peter Konrad and Kopell, {Brian H.} and Lothar Krinke and Langevin, {Jean Philippe} and Lozano, {Andres M.} and Donald Malone and Mayberg, {Helen S.} and Miller, {Jonathan P.} and Patil, {Parag G.} and Delea Peichel and Petersen, {Erika A.} and Rezai, {Ali R.} and Richardson, {R. Mark} and Patricio Riva-Posse and Tejas Sankar and Schwalb, {Jason M.} and Simpson, {Helen Blair} and Konstantin Slavin and Stypulkowski, {Paul H.} and Tor Tosteson and Peter Warnke and Willie, {Jon T.} and Zaghloul, {Kareem A.} and Neimat, {Joseph S.} and Nader Pouratian and Sheth, {Sameer A.}",
year = "2018",
month = "8",
day = "1",
doi = "10.1136/jnnp-2017-317082",
language = "English (US)",
volume = "89",
pages = "886--896",
journal = "Journal of Neurology, Neurosurgery and Psychiatry",
issn = "0022-3050",
publisher = "BMJ Publishing Group",
number = "8",

}

TY - JOUR

T1 - Charting the road forward in psychiatric neurosurgery

T2 - Proceedings of the 2016 American Society for Stereotactic and Functional Neurosurgery workshop on neuromodulation for psychiatric disorders

AU - Bari, Ausaf A.

AU - Mikell, Charles B.

AU - Abosch, Aviva

AU - Ben-Haim, Sharona

AU - Buchanan, Robert J.

AU - Burton, Allen W.

AU - Carcieri, Stephen

AU - Cosgrove, G. Rees

AU - D'Haese, Pierre Francois

AU - Daskalakis, Zafiris Jeffrey

AU - Eskandar, Emad N.

AU - Gerrard, Jason L.

AU - Goodman, Wayne K.

AU - Greenberg, Benjamin David

AU - Gross, Robert E.

AU - Hamani, Clement

AU - Kiss, Zelma H.T.

AU - Konrad, Peter

AU - Kopell, Brian H.

AU - Krinke, Lothar

AU - Langevin, Jean Philippe

AU - Lozano, Andres M.

AU - Malone, Donald

AU - Mayberg, Helen S.

AU - Miller, Jonathan P.

AU - Patil, Parag G.

AU - Peichel, Delea

AU - Petersen, Erika A.

AU - Rezai, Ali R.

AU - Richardson, R. Mark

AU - Riva-Posse, Patricio

AU - Sankar, Tejas

AU - Schwalb, Jason M.

AU - Simpson, Helen Blair

AU - Slavin, Konstantin

AU - Stypulkowski, Paul H.

AU - Tosteson, Tor

AU - Warnke, Peter

AU - Willie, Jon T.

AU - Zaghloul, Kareem A.

AU - Neimat, Joseph S.

AU - Pouratian, Nader

AU - Sheth, Sameer A.

PY - 2018/8/1

Y1 - 2018/8/1

N2 - Objective Refractory psychiatric disease is a major cause of morbidity and mortality worldwide, and there is a great need for new treatments. In the last decade, investigators piloted novel deep brain stimulation (DBS)-based therapies for depression and obsessive-compulsive disorder (OCD). Results from recent pivotal trials of these therapies, however, did not demonstrate the degree of efficacy expected from previous smaller trials. To discuss next steps, neurosurgeons, neurologists, psychiatrists and representatives from industry convened a workshop sponsored by the American Society for Stereotactic and Functional Neurosurgery in Chicago, Illinois, in June of 2016. Design Here we summarise the proceedings of the workshop. Participants discussed a number of issues of importance to the community. First, we discussed how to interpret results from the recent pivotal trials of DBS for OCD and depression. We then reviewed what can be learnt from lesions and closed-loop neurostimulation. Subsequently, representatives from the National Institutes of Health, the Food and Drug Administration and industry discussed their views on neuromodulation for psychiatric disorders. In particular, these third parties discussed their criteria for moving forward with new trials. Finally, we discussed the best way of confirming safety and efficacy of these therapies, including registries and clinical trial design. We close by discussing next steps in the journey to new neuromodulatory therapies for these devastating illnesses. Conclusion Interest and motivation remain strong for deep brain stimulation for psychiatric disease. Progress will require coordinated efforts by all stakeholders.

AB - Objective Refractory psychiatric disease is a major cause of morbidity and mortality worldwide, and there is a great need for new treatments. In the last decade, investigators piloted novel deep brain stimulation (DBS)-based therapies for depression and obsessive-compulsive disorder (OCD). Results from recent pivotal trials of these therapies, however, did not demonstrate the degree of efficacy expected from previous smaller trials. To discuss next steps, neurosurgeons, neurologists, psychiatrists and representatives from industry convened a workshop sponsored by the American Society for Stereotactic and Functional Neurosurgery in Chicago, Illinois, in June of 2016. Design Here we summarise the proceedings of the workshop. Participants discussed a number of issues of importance to the community. First, we discussed how to interpret results from the recent pivotal trials of DBS for OCD and depression. We then reviewed what can be learnt from lesions and closed-loop neurostimulation. Subsequently, representatives from the National Institutes of Health, the Food and Drug Administration and industry discussed their views on neuromodulation for psychiatric disorders. In particular, these third parties discussed their criteria for moving forward with new trials. Finally, we discussed the best way of confirming safety and efficacy of these therapies, including registries and clinical trial design. We close by discussing next steps in the journey to new neuromodulatory therapies for these devastating illnesses. Conclusion Interest and motivation remain strong for deep brain stimulation for psychiatric disease. Progress will require coordinated efforts by all stakeholders.

KW - Depression

KW - Electrical stimulation

KW - Psychiatry

KW - Stereotaxic surgery

UR - http://www.scopus.com/inward/record.url?scp=85043590945&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85043590945&partnerID=8YFLogxK

U2 - 10.1136/jnnp-2017-317082

DO - 10.1136/jnnp-2017-317082

M3 - Article

C2 - 29371415

AN - SCOPUS:85043590945

VL - 89

SP - 886

EP - 896

JO - Journal of Neurology, Neurosurgery and Psychiatry

JF - Journal of Neurology, Neurosurgery and Psychiatry

SN - 0022-3050

IS - 8

ER -